CN106822104A - 抗棘阿米巴属药物及其生产方法 - Google Patents

抗棘阿米巴属药物及其生产方法 Download PDF

Info

Publication number
CN106822104A
CN106822104A CN201610388617.4A CN201610388617A CN106822104A CN 106822104 A CN106822104 A CN 106822104A CN 201610388617 A CN201610388617 A CN 201610388617A CN 106822104 A CN106822104 A CN 106822104A
Authority
CN
China
Prior art keywords
plane
luliconazole
crystals
diffraction peaks
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610388617.4A
Other languages
English (en)
Chinese (zh)
Inventor
宫田善之
增田孝明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Publication of CN106822104A publication Critical patent/CN106822104A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201610388617.4A 2015-12-04 2016-06-02 抗棘阿米巴属药物及其生产方法 Pending CN106822104A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015237951A JP2017101009A (ja) 2015-12-04 2015-12-04 抗アカントアメーバ剤及びその製造法
JP2015-237951 2015-12-04

Publications (1)

Publication Number Publication Date
CN106822104A true CN106822104A (zh) 2017-06-13

Family

ID=56413827

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610388617.4A Pending CN106822104A (zh) 2015-12-04 2016-06-02 抗棘阿米巴属药物及其生产方法

Country Status (5)

Country Link
US (1) US20200268716A1 (https=)
JP (1) JP2017101009A (https=)
KR (1) KR20170066196A (https=)
CN (1) CN106822104A (https=)
WO (1) WO2017094204A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019150383A1 (en) * 2018-02-05 2019-08-08 Nalla Surya Prakash Rao A process for preparation of luliconazole
US12433872B2 (en) 2018-10-17 2025-10-07 Georgia State University Research Foundation, Inc. Treatment of Acanthamoeba or Balamuthia trophozoites and/or cysts

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015033612A1 (en) * 2013-09-06 2015-03-12 Pola Pharma Inc. Crystal having specific crystal habit and pharmaceutical composition containing the crystal as active ingredient
CN104619703A (zh) * 2012-09-14 2015-05-13 宝丽制药股份有限公司 具有结晶习性的晶体以及通过对所述晶体进行加工获得的药物组合物
CN105026390A (zh) * 2013-03-08 2015-11-04 宝丽制药股份有限公司 具有特异性结晶习性的晶型以及含有作为活性成分的该晶型的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60218387A (ja) 1984-04-14 1985-11-01 Nippon Nohyaku Co Ltd ケテンｓ，ｓ−アセタ−ル類
JP5812465B2 (ja) 2010-04-28 2015-11-11 学校法人玉川学園 抗アカントアメーバ用組成物、アカントアメーバ角膜炎の予防及び治療剤並びにコンタクトレンズケア溶液
CN103012385B (zh) 2012-02-17 2015-07-08 山东威智医药工业有限公司 卢立康唑的晶型及其制备方法
WO2014042231A1 (en) 2012-09-14 2014-03-20 Pola Pharma Inc. Crystal and pharmaceutical preparation containing the same crystal
JP5699234B2 (ja) 2013-06-24 2015-04-08 株式会社ポーラファルマ 結晶及び該結晶を含有してなる医薬製剤
EP3230280A4 (en) * 2014-12-12 2018-05-09 Glenmark Pharmaceuticals Limited Process for preparation of luliconazole
JP5795693B2 (ja) 2015-01-06 2015-10-14 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619703A (zh) * 2012-09-14 2015-05-13 宝丽制药股份有限公司 具有结晶习性的晶体以及通过对所述晶体进行加工获得的药物组合物
CN105026390A (zh) * 2013-03-08 2015-11-04 宝丽制药股份有限公司 具有特异性结晶习性的晶型以及含有作为活性成分的该晶型的药物组合物
WO2015033612A1 (en) * 2013-09-06 2015-03-12 Pola Pharma Inc. Crystal having specific crystal habit and pharmaceutical composition containing the crystal as active ingredient

Also Published As

Publication number Publication date
JP2017101009A (ja) 2017-06-08
US20200268716A1 (en) 2020-08-27
WO2017094204A1 (en) 2017-06-08
KR20170066196A (ko) 2017-06-14

Similar Documents

Publication Publication Date Title
CN105980390B (zh) 一种jak激酶抑制剂的硫酸氢盐的结晶形式及其制备方法
CN105026390B (zh) 具有特异性结晶习性的晶型以及含有作为活性成分的该晶型的药物组合物
CN109942546B (zh) 喹诺酮嘧啶类化合物及其制备方法和应用
JP6215827B2 (ja) キサントン化合物の誘導体
JP6902025B2 (ja) 聴覚損失の予防および治療のための方法および組成物
EP2739621B1 (en) 2-acylaminothiazole compound crystals
CN107056813B (zh) 德罗格韦钠盐的晶型及其制备方法
CN105189513A (zh) 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态
CN106822104A (zh) 抗棘阿米巴属药物及其生产方法
CN101805387A (zh) 一种醋丙甲泼尼龙新晶型与制备方法
US10988444B2 (en) Antimicrobial compounds
CN102241628B (zh) (2e)-3-苯基-n-[2,2,2-三氯-1-[[(8-喹啉基氨基)硫代甲基]氨基]乙基]-2-丙烯酰胺及其医药用途
WO2011140682A1 (zh) （2e）-3-苯基-n-[2，2，2-三氯-1-[[（8-喹啉基氨基）硫代甲基]氨基]乙基]-2-丙烯酰胺及其医药用途
US20130102628A1 (en) Crystal of fused pyridine compound salt
JP7849971B2 (ja) テトラメチルピラジンニトロンの結晶形、製造方法及び使用
WO2022183964A1 (zh) 一种8-(吡啶三氮唑)取代香豆素类化合物及其制备方法和应用
CN102453028A (zh) 抗真菌剂—2-[（2，3-二氢-4H-苯并[b]噻喃-4-亚基）亚肼基]-4-氧代四氢噻（噁）唑-5-乙酸衍生物
KR20050059132A (ko) 신규 결정
US20240216281A1 (en) Manufacturing method of medication
JP7758278B2 (ja) コロナウイルス科感染症の治療又は予防
US20210283213A1 (en) Crystal of polymyxin b1 sulfate, polymyxin b2 sulfate or their mixture and preparation method thereof
Ahmed Mousa et al. Synthesis, Characterization and Antibacterial Activity of Ciprofloxacin Loaded Nanoparticles
CN117986197A (zh) 三嗪腙类化合物、其制备、含其的药物组合物及其应用
WO2024062389A1 (en) Crystalline polymorph forms of a trpv1 antagonist and formulations thereof
CN105902539A (zh) 抗三毛滴虫剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170613

WD01 Invention patent application deemed withdrawn after publication